Today is a day dedicated to recognizing interns and celebrating the future leaders of the world. At Hummingbird Bioscience, interns get to learn about drug discovery and development and contribute to the team’s strategy and operational excellence. Earlier this year, we held an internship showcase to share our interns’ work with the rest of the team. Happy Intern Day to all our interns, past and present! Check out what our interns said about working at Hummingbird Bioscience. #internships #biotech
Hummingbird Bioscience
Biotechnology Research
Hummingbird Bioscience is an innovative clinical-stage biotech company with operations in Singapore and the US.
About us
Hummingbird Bioscience is a data-driven precision biotherapeutics team discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. Sign up for our updates here: https://bit.ly/HMBDNews
- Website
-
https://hummingbirdbioscience.com/
External link for Hummingbird Bioscience
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Singapore
- Type
- Privately Held
- Founded
- 2015
Locations
-
Primary
61 Science Park Road, #06-15/24
The Galen
Singapore, 117525, SG
-
51 Science Park Road #04-01/11
The Aries
Singapore, 117586, SG
-
TMC Innovation
2450 Holcombe Blvd Suite X
Houston, Texas 77021, US
Employees at Hummingbird Bioscience
-
Angele Maki
Dealmaker | Leader | Scientist
-
Gary Khoo 邱思贤
CMC and Product Development Operations in: ADCs/ Cell Therapies-Viral Vectors/ Innovating & Building Start-ups
-
Brendon J. Hanson
VP Discovery and Research Platforms at Hummingbird Bioscience
-
Qihui Seet
Assoc Director Clinical Biomarkers at HMBD
Updates
-
Lisa Ooi, Senior Vice President of Strategy, had the opportunity to share her professional journey and what led her to Hummingbird Bioscience with Nucleate Singapore. Lisa and Jessie Wong Ling Ai also discussed the company’s ADC platform and technologies, our clinical-stage therapies and our approach to precision oncology. Listen here: https://bit.ly/3W6SCot #nucleate #biotech #singapore
🎙 Nucleate Singapore Pulse 👩🔬 This month, Nucleate Singapore interviewed Dr. Lisa Ooi, Senior Vice-President of Strategy at Hummingbird Bioscience. Hummingbird Bioscience is a Singapore-based clinical-stage biotherapeutics company specialising in novel antibody-based methods for precision therapeutics to treat cancer. 🎧 In this episode, Dr. Lisa Ooi dives into the science behind treating oncology with Hummingbird Bioscience's novel and differentiated antibody-based platform technology, and key considerations for advancing potential assets and technologies. Additionally, she shares some reasons behind the founders' decision to start Hummingbird Bioscience in Singapore, factors behind their successful fundraising rounds, and benefits of active participation in the biotech ecosystem. Listen and follow us on Spotify 👉 https://lnkd.in/gVjHtaYR Apple Podcasts 👉 https://lnkd.in/g6PJiMWd Show notes and transcripts 👉 https://lnkd.in/gXyZg_va Podcast team: John Joson Ng and Jessie Wong Ling Ai Nucleate team: Liyana Ayub Ow Yong Kim Whye Leong Jiang Yeow Ignacius Tay Samantha Wong Ivan Seah, MBBS/MBA/MPH Ying Tong Yeo Shruti Sridhar Gloria Chan Isha Karnik Hana Maldivita Tambrin Jashan Singh Diya Srivastava Dillon Chew Dijin Zhang Panida Cen Senuri De Silva #NucleateSingapore #Podcast #Hummingbirdbioscience #antibody #oncology #cancer
-
-
Kon Yew Kwek, BMBCh, DPhil, Senior Vice President of Clinical Development at Hummingbird Bioscience will share our clinical development strategy and progress at the SCRI Clinical Trials Symposium 2024 (30-31 July): https://bit.ly/3xIprzF Kon Yew will also participate in a panel discussing the possibilities for biotechs conducting clinical trials in Singapore. 31 July 2024 (Day 2) Time: 11 am – 12.30 pm Organized by the Singapore Clinical Research Institute (SCRI), the two-day event aims to showcase the impact of and opportunities for clinical trials in Singapore. #clinicaldevelopment #clinicaltrials #singapore
-
-
Hummingbird Bioscience partnered with the Children's Wishing Well to spark children’s interest in biology and conservation. In a visit to Science Centre Singapore last month, volunteers from our team accompanied ~40 children on the “Young Geneticist Trail”, for the children to learn about DNA and genetic inheritance. The children also viewed a screening of the “Jane Goodall – Reasons for Hope” documentary at the Omni-theatre. We hope the children enjoyed their day! #csr #scienceeducation #biology
-
-
Gary Khoo 邱思贤, VP of CMC at Hummingbird Bioscience will speak at a panel at World ADC Asia (25-27 June, Incheon, South Korea). Gary will share about how we manage our ADC production processes. The panel will discuss supply chain management of ADC components in Asia Pacific, and navigation of European and American markets. If you will be at World ADC Asia, connect with Gary at the panel discussion. #worldADC #ADC World ADC Event Series
-
-
Hummingbird Bioscience’s Chief Business Officer Angele Maki will be at the BIO International Convention (3-6 June, California). If you will be at the convention, connect with Angèle via the BIO One-on-One Partnering system to receive the latest updates on our clinical programs and our proprietary dual-payload #ADC platform. #BIO2024
-
-
Hummingbird Bioscience’s next-generation ADC platform and capabilities have been featured in a BioCentury Inc. article: https://bit.ly/3V0c4mB (for subscribers) Our team has developed a proprietary platform and pipeline of dual-payload ADCs designed to deliver the optimal combination of payloads, carefully selected to address tumor resistance to earlier generation ADCs. Read more about our #ADC technologies in the article, or connect with us to learn more.
-
-
Hummingbird Bioscience’s Chief Scientific Officer Jerome Boyd-Kirkup, Chief Business Officer Angele Maki and SVP Clinical Development Kon Yew Kwek, BMBCh, DPhil will be at ASCO 2024 (31 May – 4 June). If you will be in Chicago for #ASCO2024, meet with us to learn more about our proprietary dual-payload antibody-drug conjugate platform which has the potential to overcome resistance with current ADCs. Read our recent press release to learn more about our #ADC capabilities: https://bit.ly/3UGUYd0
-
-
Hummingbird Bioscience will present its next-generation antibody-drug conjugate capabilities (ADC) at PEGS Boston 2024 (13-17 May). For the first time, the company will present how its proprietary 4th generation ADC platform overcomes the resistance observed with earlier generation single payload ADCs. The company will also present how its proprietary Rational Antibody Discovery (RAD) platform enables epitope-directed discovery against challenging targets for optimal drug properties. Read more on the press release: https://bit.ly/3UGUYd0
-
Warm congratulations to the Endeavor BioMedicines team for the Series C financing. We are excited to see ENV-501's (previously HMBD-501) planned entry to the clinic later this year. Read more on Fierce Biotech: https://bit.ly/3WfJJdW
-